We investigated whether canagliflozin improved peak VO2 and ventilatory efficiency in patients with T2DM and HFrEF compared to sitagliptin, a dipeptidyl peptidase (DPP)4 inhibitor with proven cardiovascular safety with glucose‐lowering efficacy similar to SGLT2 inhibitors.11 This evidence concerns the gene DPP4 and type 2 diabetes mellitus.